2026 IPO-issuance-broadening monitor — reading #2 (July): gate stays YELLOW, but the speculative tail has started to re-form

Desk Note Ticker Tape

Article published Aug 3, 2026. Prices below use latest available snapshots.

SPCX $146.23 +17.9% 30d QQQ $729.87 +5.0% 30d SPY $772.67 +4.0% 30d

hot-take · self

Second reading of the standing 2026 IPO-issuance-broadening monitor. The June base-rate work set the escalation gate: a regime top upgrades from yellow to red only if the giga-deals are followed by a broad issuance wave — the robust Baker-Wurgler condition — and not if they stay three concentrated deals. Reading #1 at the H1 close found issuance elevated but narrowing, and kept the gate yellow.

July is the first month where that picture cracks. The headline count still says "no flood." The composition says the speculative tail has started to re-form.

The three metrics (July close)

(1) Count — flat on the broad measure, still shrinking on the strict one.

  • Broad count including blank-check vehicles: 215 US IPOs year-to-date, which annualizes to roughly 369 against 347 for all of 2025 — a hair above last year, essentially unchanged from the pace reading #1 measured a month ago.
  • Traditional deals only: 93 priced year-to-date, −24.4% against the same point last year, annualizing to about 159 against 202 in 2025.
  • July itself produced 20 deals.

The two measures disagree, and the disagreement is the finding rather than a nuisance: the gap between them is the blank-check tail, and it widened this month.

(2) Composition — the actual news, and it points the other way from reading #1.

Of July's 20 deals, 12 were blank-check vehicles — 60% of the month's count. Reading #1 described a market of "a small group of very large, scaled companies in favored sectors," concentrated into aerospace/defense and AI-infrastructure. July does not look like that. The operating companies that priced were a rare-earths miner, two biotechs, a nuclear-fuel name, a sandwich franchise, and a memory manufacturer — the sector list stopped being a two-sector list.

That is what broadening looks like at the beginning: not a higher count, but a wider and lower-quality one. Blank-check formation is the classic vehicle for the speculative tail, and the dispersion in outcomes already shows the quality spread — one nuclear-fuel listing sits roughly −48% from its offer price while a biotech sits +61%, both inside the same three weeks.

(3) Proceeds concentration — extreme, and pulling in the opposite direction.

Traditional deals raised $144.0B year-to-date, +631% against the same point last year on a count that fell 24%. That works out to about $1.55B per deal against roughly $160M a year ago — call it a tenfold jump in average deal size.

So the dollars are more concentrated than they have been in years while the deal list gets longer and scruffier. Both things are true at once, and they are the two halves of the gate arguing with each other.

The day-1 pop metric remains unavailable, for the second reading running. No clean 2026-isolated first-day average is free-sourceable; the trackers that publish one blend 2024–2026 into a single ~18% figure, against a ~19% long-run baseline and the 29.3% that 2025 printed. The since-offer returns quoted above are not first-day pops and should not be read as such.

What changed in the catalyst

Reading #1 named the specific thing to watch: whether the OpenAI/Anthropic S-1 window pulls a tail of smaller speculative deals public behind it. That window has now split in half.

  • Anthropic confidentially filed on June 1 and is still pointed at an October Nasdaq listing, with a public S-1 expected around September.
  • OpenAI confidentially filed on May 22 but is now leaning toward 2027, per Bloomberg reporting in late June, citing market volatility and a hard floor on valuation.

Half the catalyst just moved out by a year. That materially lowers the odds of a near-term flood even though the tail has begun to form on its own.

One thing this reading explicitly does not claim

July's violent drawdown in the AI-infrastructure complex was not this gate firing. That move was one leveraged fund being liquidated and selling its book in a single block — index volatility never confirmed it, with the VIX peaking at 20.66 and finishing the month lower than it started, against a max S&P drawdown of −3.4%. A concentrated forced unwind and an issuance-driven regime top are different mechanisms, and reading the first as evidence for the second would be the easiest available mistake this month.

Verdict — gate STAYS YELLOW, with the internal state upgraded

No red escalation. But the reading changes from "concentrated, not broadening" to concentrated in dollars, broadening in count and composition — the first genuine instance of the thing this monitor was set up to catch.

It does not escalate yet because the strict count is still down 24% year over year, the froth input cannot be measured, and the single largest broadening catalyst just deferred to 2027.

What flips it red: blank-check formation sustaining at 10+ per month for two more months, and the non-blank-check speculative count turning positive year over year, and Anthropic's October listing being followed inside roughly eight weeks by a tail of smaller AI-adjacent deals. That sequence — tail first, mega-deal second, more tail third — is the wave; a single crowded month is not.

Next check

~September 1, with a second look immediately after Anthropic's public S-1 lands, since that is now the live catalyst rather than one of two. Two specific things to carry in: whether blank-check formation held its July pace, and whether the biotech window that cracked open in July kept widening.

The first-day-pop input has now failed to source twice at monthly cadence. Next reading either narrows it to non-blank-check deals on a quarterly basis or drops it and says so — a metric that cannot be measured should not keep appearing in a gate as though it were being checked.

Sources